Reuters logo
BRIEF-Janssen submits NDA for Apalutamide(ARN-509) to FDA
2017年10月11日 / 下午1点39分 / 9 天前

BRIEF-Janssen submits NDA for Apalutamide(ARN-509) to FDA

Oct 11 (Reuters) - Johnson & Johnson

* Janssen submits new drug application to U.S. FDA for Apalutamide (ARN-509) to treat men with non-metastatic castration-resistant prostate cancer

* Janssen Biotech Inc says submission of the NDA for apalutamide​ is based on Phase 3 data from pivotal ARN-509-003 (SPARTAN) clinical trial Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below